Andrew B. Yaffa Examines Emerging Products Liability Risks in Regenerative Medicine in Daily Business Review

As regenerative medicine continues to evolve, new questions are emerging about patient safety, regulatory oversight, and legal accountability.

In a recent article published in the Daily Business Review, Andrew B. Yaffa, Co-Founder and Managing Partner of Grossman Yaffa Cohen, examines the growing market for stem cell therapies and other regenerative treatments and the potential products liability implications when patients suffer serious injuries.

Titled “Regenerative Medicine’s Growth Raises New Products Liability Questions,” the article explores why injuries involving regenerative treatments may require legal investigation beyond traditional medical malpractice. Andy highlights the importance of examining how biological products are manufactured, marketed, regulated, and administered, as well as whether patients received accurate information about their safety and effectiveness.

Drawing on his experience representing patients harmed by stem cell procedures, including cases involving devastating vision loss, Andy underscores the importance of distinguishing legitimate medical innovation from treatments promoted without sufficient scientific support.

As emerging therapies continue to enter the marketplace, the article reinforces a critical consideration: When patient harm involves a regenerative product, accountability may extend beyond the medical procedure itself.

Read Andrew B. Yaffa’s full article in the Daily Business Review.